Insulet Corp. (PODD) Operating Income
The operating income for Insulet Corp. (PODD) is $473.80M with a period-over-period change of +53.38%. Operating income measures profit from core operations before interest and taxes.
PODD Operating Income Chart
Reported annual fiscal-period values; no daily interpolation.
PODD Quarterly Operating Income Growth (YoY)
Operating Income growth vs the same quarter one year earlier, last 20 quarters.
Operating Income History
| Date | Operating Income | % Change |
|---|---|---|
| 2025 | $473.80M | +53.38% |
| 2024 | $308.90M | +40.41% |
| 2023 | $220.00M | +485.11% |
| 2022 | $37.60M | (70.16%) |
| 2021 | $126.00M | +144.66% |
| 2020 | $51.50M | +3.00% |
| 2019 | $50.00M | +82.48% |
| 2018 | $27.40M | +470.27% |
| 2017 | ($7.40M) | +30.87% |
| 2016 | ($10.70M) | +78.04% |
| 2015 | ($48.74M) | (449.20%) |
| 2014 | ($8.87M) | +69.54% |
| 2013 | ($29.14M) | +19.00% |
| 2012 | ($35.97M) | +15.30% |
| 2011 | ($42.47M) | (9.92%) |
| 2010 | ($38.63M) | +34.92% |
| 2009 | ($59.36M) | +33.56% |
| 2008 | ($89.34M) | (65.93%) |
| 2007 | ($53.84M) | (55.41%) |
| 2006 | ($34.65M) | (61.10%) |
| 2005 | ($21.50M) | (51.95%) |
| 2004 | ($14.15M) | (17.80%) |
| 2003 | ($12.01M) | +5.19% |
| 2002 | ($12.67M) | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy